Mark Adams Acquires 88,999 Shares of Venture Life Group (LON:VLG) Stock

Key Points

• Mark Adams, an insider at Venture Life Group, acquired 88,999 shares at a price of GBX 56 per share, totaling approximately £49,839.44 on October 3rd.
• Venture Life Group's stock recently traded at GBX 55, with a market capitalization of £70.43 million and a PE ratio of -22,000.00.
• The company reported GBX 0.83 EPS for its latest quarter, reflecting a net margin of 1.44% and a projected earnings per share of 6.14 for the current fiscal year.

Venture Life Group plc (LON:VLG - Get Free Report) insider Mark Adams purchased 88,999 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The stock was acquired at an average price of GBX 56 per share, for a total transaction of £49,839.44.

Venture Life Group Stock Performance

Shares of VLG stock traded down GBX 1 on Friday, hitting GBX 55. The company's stock had a trading volume of 747,391 shares, compared to its average volume of 330,570. The company has a debt-to-equity ratio of 28.45, a quick ratio of 1.48 and a current ratio of 2.22. The stock's 50 day moving average is GBX 58.53 and its 200-day moving average is GBX 51.68. Venture Life Group plc has a fifty-two week low of GBX 32 and a fifty-two week high of GBX 66. The company has a market capitalization of £70.43 million, a PE ratio of -22,000.00, a PEG ratio of 5.67 and a beta of 0.30.

Venture Life Group (LON:VLG - Get Free Report) last released its quarterly earnings results on Tuesday, September 30th. The company reported GBX 0.83 EPS for the quarter. Venture Life Group had a net margin of 1.44% and a return on equity of 0.99%. Equities research analysts expect that Venture Life Group plc will post 6.1391542 earnings per share for the current fiscal year.

Venture Life Group Company Profile

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.